Filed with ASX · · 5 pages · English
The agreement, valued at a specified amount, involves assessing the trial's design and interim results to identify potential issues. TrialKey's capabilities include using machine-learning models to enhance clinical trial design and risk assessment. This engagement marks a significant step in TrialKey's commercial application of its services within the biotech sector.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX ANNOUNCEMENT 10 November 2026 TrialKey secures Paradigm contract and expands clinical trial capabilities Highlights • TrialKey has signed a services agreement with Paradigm to provide an independent evaluation of its PARA_OA_012 Phase 3 osteoarthritis study. • TrialKey will independently...
Follow Pathkey.AI into a list and get an email when it puts out news.
Follow Pathkey.AI